公开(公告)号：US20220062229A1

公开(公告)日：2022-03-03

申请号：US17223229

申请日：2021-04-06

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Seth Hopkins ,  Kenneth Koblan ,  Antony Loebel ,  Ajay Ogirala

IPC: A61K31/381 ,  A61P25/18

Abstract: Provided herein are methods for determining if a compound has potential efficacy for the treatment for a specific symptom domain of schizophrenia, such as for example, the treatment of a negative symptom of schizophrenia. In addition, provided herein are methods of determining the prominent symptom domain of a subject suffering from schizophrenia. Further, provided herein are various methods for the treatment of the negative symptoms, cognitive dysfunction symptoms, or both, associated with schizophrenia comprising administering to a subject a therapeutically or prophylactically effective amount of various compounds.

公开(公告)号：US11129807B2

公开(公告)日：2021-09-28

申请号：US16486257

申请日：2018-02-16

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Seth Hopkins ,  Kenneth Koblan ,  Antony Loebel ,  Ajay Ogirala

IPC: A61K31/381 ,  A61P25/18

Abstract: Provided herein are methods for determining if a compound has potential efficacy for the treatment for a specific symptom domain of schizophrenia, such as for example, the treatment of a negative symptom of schizophrenia. In addition, provided herein are methods of determining the prominent symptom domain of a subject suffering from schizophrenia. Further, provided herein are various methods for the treatment of the negative symptoms, cognitive dysfunction symptoms, or both, associated with schizophrenia comprising administering to a subject a therapeutically or prophylactically effective amount of various compounds.